Prevalence Of Rapid Acetylator Phenotype In Myanmar Type 2 Diabetes Mellitus Patients

H Htet, NHH Win. 1SEGi University, Kuala Lumpur, Malaysia, 2University of Medicine (1) Yangon, Yangon, Myanmar

Introduction: Type 2 diabetes mellitus is among the important non-communicable diseases which have become a big economic and social burden in the modern world including Myanmar. Many studies have stated that there is an association between rapid acetylator phenotype and type 2 diabetes mellitus (1-4). Acetylator phenotypes has also been associated with increased incidence of diabetic mellitus-related complications (5, 6).

Materials and methods: Acetylator phenotyping was done on 63 Myanmar type 2 diabetes mellitus patients using the simplified method of Hasse Schröder (7). Sulphadimidine (10mg/kg orally with 200 mL water) was given and participants were asked to void urine once 4 hours after ingestion. Those urine samples were discarded. Participants were then requested to void urine once between 4 and 6 hours after ingestion. These urine samples were used for identification of acetylator phenotype. Interpretation of acetylator phenotype was according to the developed urine colour after a series of addition of chemical reagents and hydrolyzing in the water bath. Each sample was tested at least three times for confirmation. Analysis was performed using microsoft Excel®.

Result: Among 63 participants (8), 53.97% (n=34) were rapid acetylators and 46.03% (n=29) were slow acetylators (Table 1, Figure 1).

Conclusion: Although previous studies stated that rapid acetylator phenotype was associated with increased incidence of type 2 diabetes mellitus, this study could not conclude that rapid acetylator phenotype was a predisposing factor for type 2 diabetes mellitus in a Myanmar population.

Table (1) Distribution of rapid and slow acetylator status among type 2 diabetes mellitus

Fig (1) Distribution of rapid and slow acetylator phenotype among type 2 diabetes mellitus

(1) Evans et al. (1985). Journal of Medical Genetics 9: 57-59.

(2) Irshaid et al. (1992). European Journal of Clinical Pharmacology 43(6): 621-623.

(3) Burrows et al. (1978). British Medical Journal 1(6107): 208-210.

(4) Mattila MJ and Tiitinen H (1967). Annles Medicinae Experimentalis et Biologiae Fenniae 45:423-7.

(5) Banjoko SO and Akinlade KS (2010). Ind J Clin Biochem 25(3): 289-294.

(6) Glowinski et al. (1982). J. Biol. Chem: 257: 1424-1430.

(7) Schröder H (1972). British Medical Journal 3:506-507.

(8) From the Pharmacology 2014 Meeting: Proceedings of the British Pharmacological Society, pa2online.org, volume 12, issue 3, abstract entitled ‘Distribution Of Rapid Acetylator Phenotype In Myanmar (Burma) And Its Distribution Across The World’